Test Price
2,800 AED✅ Home Collection Available
SLC33A1 Gene (SPG42) Genetic Test in UAE - 2800 AED - DNA Labs UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited NGS processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM – 11 PM daily).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation included, delivered by a DHA-licensed clinical geneticist.
- Insurance Support: Direct Billing Verification via WhatsApp +971 54 548 8731 (24/7 automated check).
Test Overview & Methodology
This test screens the SLC33A1 gene for pathogenic variants causing hereditary spastic paraplegia type 42 (SPG42), a rare neurodegenerative disorder presenting with progressive leg weakness and spasticity. Using Next‑Generation Sequencing (NGS), every coding exon is analyzed with bioinformatic pipelines validated against ACMG guidelines. The analysis includes copy number variation (CNV) detection for comprehensive coverage.
Targeted Specialists
- Neurologist – diagnostic workup of spastic paraplegia
- Clinical Geneticist – family risk stratification and counselling
- At-Risk Individuals – proactive genetic insight
| Feature | Our NGS Test | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Precision | 99.9% analytical sensitivity / specificity | ~95% for targeted regions only |
| Method | NGS (Illumina NovaSeq) + CNV calling | Sanger sequencing, limited to a few exons |
| Turnaround | 3–4 weeks (with interim report option) | 6–8 weeks |
Physician Insight & Safety Protocols
“A positive result on this SLC33A1 test does not, in itself, confirm a definitive diagnosis; it must be interpreted within the context of your full clinical picture, imaging findings, and family history. Our team of clinical geneticists will guide you through a post‑test consultation to ensure you understand the implications for treatment, surveillance, and family planning.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA License 9294403
Important Clinical Advisory
Do not discontinue any prescribed medication or alter your neurological therapy plan without prior consultation with your treating physician. Genetic test results are not a substitute for continuous medical supervision.
Exclusion Criteria & ER Red Flags
- Sample Exclusion: Samples with EDTA tubes past expiry, gross hemolysis, or microbial contamination will be rejected.
- Patient Ineligibility: Individuals unable to provide valid informed consent or a complete clinical history; minors must have legal guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Emergency Red Flags: If you experience sudden loss of ability to walk, severe muscle rigidity with fever, or breathing difficulties, call 998 (UAE Ambulance) immediately. These symptoms require urgent neurological assessment and are not addressed by a scheduled genetic test.
Patient FAQ & Clinical Guidance
1. What is the SLC33A1 (SPG42) genetic test?
The SLC33A1 gene analysis uses next-generation sequencing to identify mutations causing hereditary spastic paraplegia SPG42. This test examines all coding regions and exon–intron boundaries of the SLC33A1 gene, providing a definitive genetic diagnosis for SPG42-associated neurodegenerative disease. Results are interpreted according to ACMG/AMP variant classification standards, and a board‑certified clinical geneticist reviews each case.
2. Who should consider this genetic test?
Those with progressive spastic paraplegia family history or unexplained neurological symptoms should consider genetic testing. This includes individuals with gait disturbances, muscle stiffness, or hyperreflexia of unknown cause, as well as asymptomatic relatives of a known SPG42 patient. Genetic counselling is mandatory prior to testing and is integrated into our service pathway.
3. How is the sample collected and what is the turnaround time?
A home blood draw or FTA card yields genetic results within three to four weeks. Our VIP mobile phlebotomy team arrives at your doorstep between 8 AM and 11 PM, using either a standard EDTA tube for whole blood or a simple finger‑prick onto an FTA card. The sample is transported in an ISO‑certified cold chain, and you will receive a secure PDF report with an optional tele‑consultation.
UAE Regulatory & Data Privacy Adherence
Our laboratory operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is handled with strict confidentiality, encrypted storage, and access-controlled systems. Patient consent is obtained per Federal Decree-Law No. 4 of 2016 on Medical Liability. Your results are only shared with you and your designated healthcare provider.
Clinical & Logistical Metadata
| Test Name | SLC33A1 Gene (SPG42) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) with CNV Analysis |
| ICD-10-CM Code | G11.4 (Hereditary Spastic Paraplegia) |
| LOINC Code | 96799-3 (SLC33A1 gene mutation analysis in Blood by Sequencing) |
| DHA Facility License & Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians